Shanghai-based pharmaceutical manufacturer selling drugs in China.
Shanghai-based pharmaceutical manufacturer selling drugs in China.
Moat: none
Headquarters: Shanghai, China · Employees: 437
Size Shanghai Yizhong Pharmaceutical (688091.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.00B, the 2159th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥32.66 on 18 Nov 2026.
Performance Over six months the shares fell 48.5%, against -10.6% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 32.1% over the last twelve months (peer median +7.1%); the operating margin is 13.6% (peer median 8.9%).
Valuation It trades at 19.3× enterprise value to sales against a peer median of 3.2× (2nd most expensive of 18).
Capital Return on invested capital runs 1.1 points below its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥326M | CN¥315M | CN¥173M | CN¥359M | CN¥235M |
| Revenue growth | — | +83% | -52% | +53% | — |
| Gross profit | CN¥285M | CN¥260M | CN¥158M | CN¥335M | CN¥217M |
| EBITDA | n/a | CN¥57.7M | -CN¥4.15M | CN¥168M | CN¥116M |
| Net income | CN¥69.7M | CN¥64.6M | CN¥6.98M | CN¥162M | CN¥143M |
| Free cash flow | -CN¥21.1M | -CN¥143M | -CN¥68.0M | CN¥73.6M | CN¥101M |
| Capital expenditure | CN¥58.5M | CN¥130M | CN¥80.0M | CN¥8.78M | CN¥35.9M |
| Total debt | CN¥25.0M | CN¥25.5M | CN¥0 | CN¥44.0M | CN¥0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688091.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -10.0% | -5.0% | 7th lowest of 21 |
| 6-month return | -48.5% | -10.6% | 2nd lowest of 21 |
| Distance from 52-week high | -50.7% | -32.1% | 5th lowest of 21 |
| Revenue growth (TTM) | +32.1% | +7.1% | 2nd highest of 18 |
| Operating margin | 13.6% | 8.9% | 7th highest of 18 |
| EV / Sales | 19.3× | 3.2× | 2nd most expensive of 18 |
| ROIC minus cost of capital | -1.1 pp | +0.5 pp | 6th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.00B | -49% | +32% | 14% | 19.3× | n/a | n/a |
| Aurisco Pharmaceutical 605116.SS | China | $1.00B | -23% | +3% | 25% | 4.2× | -2.0% | +18.7% |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1,000M | +17% | +24% | 6% | 5.2× | 12.7% | +19.4% |
| SAWAI 4887.T | Japan | $1.01B | -18% | +2% | 9% | 1.3× | n/a | n/a |
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $989M | -9% | +8% | 7% | 1.4× | 2.3% | +1.8% |
| Renhe Pharmacy 000650.SZ | China | $1.01B | -12% | -7% | 14% | 0.9× | -10.7% | -7.0% |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.02B | +1% | +27% | 4% | 2.3× | 4.3% | +3.5% |
| Aarti Pharmalabs AARTIPHARM.NS | India | $984M | +44% | +13% | 18% | 4.7× | n/a | n/a |
| InventisBio 688382.SS | China | $982M | -47% | -61% | -563% | 75.0× | 6.5% | -60.6% |
| Chongqing Taiji Industry (Group) 600129.SS | China | $982M | -20% | -4% | 2% | 1.3× | n/a | n/a |
| Seaport Therapeutics SPTX | United States | $980M | +16% | n/a | n/a | n/a | n/a | n/a |
| Procter & Gamble Health PGHL.NS | India | $979M | +3% | +13% | 31% | 6.3× | 5.6% | +9.3% |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.02B | -23% | +103% | 24% | 4.0× | 7.5% | -4.5% |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.03B | -33% | -2% | 13% | 4.2× | 4.4% | +7.7% |
| Nxera Pharma 4565.T | Japan | $974M | +46% | +24% | 14% | 5.4× | 17.7% | +27.3% |
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -10% | +7% | 9% | 1.2× | -0.3% | +12.1% |
| Sunflower Pharmaceutical 002737.SZ | China | $1.04B | -11% | +31% | -7% | 1.7× | -6.5% | -7.7% |
| Savara SVRA | United States | $1.04B | -7% | n/a | n/a | n/a | n/a | n/a |
| BeBetter Med 688759.SS | China | $960M | -58% | n/a | n/a | n/a | n/a | n/a |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.04B | +33% | +5% | 24% | 3.2× | -5.6% | +12.7% |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $959M | -21% | -27% | -19% | 2.5× | n/a | n/a |